Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

• Status: Terminated
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
• Treatments: Gemcitabine; Oxaliplatin

Criteria

Inclusion Criteria:

• Transitional cell carcinoma

• Histologically-proven

• Locally advanced unresectable or metastatic

• With at least one measurable target

• Informed consent signed

Exclusion Criteria:

• Previous chemotherapy

• Previous radiotherapy

• Performance status >=2

• Peripheral neuropathy >=1